CK1-IN-3c

CAS No. 756805-89-7

CK1-IN-3c( —— )

Catalog No. M15877 CAS No. 756805-89-7

CK1-IN-3c is a novel casein kinase 1δ/ε (CK1δ/ε) inhibitor with IC50 of 1.6 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CK1-IN-3c
  • Note
    Research use only, not for human use.
  • Brief Description
    CK1-IN-3c is a novel casein kinase 1δ/ε (CK1δ/ε) inhibitor with IC50 of 1.6 uM.
  • Description
    CK1-IN-3c is a novel casein kinase 1δ/ε (CK1δ/ε) inhibitor with IC50 of 1.6 uM; shows selectivity over CDK5/p25, GSK-3α/β, and DYRK1A; elicits selective cytotoxic activity against the PANC-1 cell line.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Casein Kinase
  • Recptor
    Casein Kinase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    756805-89-7
  • Formula Weight
    347.378
  • Molecular Formula
    C19H17N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    6,7-dimethoxy-N-(5-phenyl-1H-pyrazol-3-yl)quinazolin-4-amine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Karthikeyan C, et al. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2663-2667.
molnova catalog
related products
  • Casein kinase 1δ-IN-...

    Casein kinase 1δ-IN-6 is a potent and selective inhibitor of the protein kinase CK-1δ with an IC50 of 23 nM, demonstrating neuroprotective and anti-inflammatory activity in both in vitro and in vivo assays. Casein kinase 1δ-IN-6 can be used to study neurodegenerative diseases.

  • Quinalizarin

    Quinalizarin is a potent, selective and cell-permeable inhibitor of CK2 with Ki of 58 nM.

  • CK2/ERK8-IN-1

    CK2/ERK8-IN-1 is a dual inhibitor of casein kinase 2 (CK2) (Ki: 0.25 μM) and ERK8 (IC50s: 0.50 μM) with pro-apoptotic efficacy.